Prognostic value of CD20 antigen mediated immune checkpoint inhibition in patients with acute or chronic lymphocytic leukemia: A protocol for systematic review

BACKGROUND: The addition of rituximab to standard chemotherapy has been shown to improve response rates in patients with acute or chronic lymphocytic leukemia. However, the prognostic factors associated with progression-free survival in rituximab treated patients with lymphocytic leukemias remains u...

Descripción completa

Detalles Bibliográficos
Autores principales: Mkhwanazi, Zekhethelo A., Mfusi, Snenhlanhla A., Nkambule, Bongani B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282114/
https://www.ncbi.nlm.nih.gov/pubmed/35363193
http://dx.doi.org/10.1097/MD.0000000000028868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282114/
https://www.ncbi.nlm.nih.gov/pubmed/35363193
http://dx.doi.org/10.1097/MD.0000000000028868

Ejemplares similares